EUVIMEDEUVIMED entdecken
Crossref

Plasma pTau217/Aβ 42 and pTau217 outperform pTau181/Aβ 42 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study

Daniele Imperiale iD, Andrea Marcinnò, Cristiana Atzori, Daniele Pio Angeloro, Amelia Murgioni, Alessia Bagatin, Valentina Secci, Andrea Calcagno, Marco Alfonso Capobianco, Mario Coletti Moja iD, Eugenia Rota, Mara Rosso und 9 weitere

Journal of Alzheimer’s Disease · 2025

DOI: 10.1177/13872877251390897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Daniele Imperiale und 20 weiteren Autor:innen. Beteiligte Einrichtung: SC Neurologia, Ospedale Maria Vittoria, Torino, Italy. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, tau Proteins, Peptide Fragments, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer's disease (AD) diagnosis often relies on invasive cerebrospinal fluid (CSF) sampling or expensive cerebral positron emission tomography (PET) imaging. Noninvasive tests could facilitate early detection. Plasma phosphorylated-tau (pTau) isoforms are promising AD biomarkers that correlate with brain amyloid-β (Aβ) deposition.

Objective

To explore the diagnostic accuracy of pTau-based plasma biomarkers to forecast CSF amyloid-positive status in a real-world consecutive population of subjects with cognitive impairment and complete plasma and CSF biomarker profiles.

Methods

We retrospectively studied 138 consecutive patients with cognitive impairment. Plasma biomarkers (pTau217, pTau181, Aβ 42 , Aβ 40 ) were measured by automated immunoassay. Diagnostic accuracy for CSF amyloid status was assessed using area-under-the curve (AUC) values from receiver-operating characteristic (ROC) curve analysis. A dual-threshold strategy was used to define low- and high-risk groups and estimate how many lumbar punctures could be avoided.

Results

Among 138 patients (37% CSF amyloid-positive), pTau217/Aβ 42 ratio had the highest AUC (0.920) for predicting amyloid positivity, followed by pTau217 (AUC 0.904). These values exceeded the accuracy of pTau181-based markers. Using dual cut-offs, a 90% sensitivity-90% specificity strategy could avoid about 93.5% of lumbar punctures using pTau217/Aβ 42 (10.9% misclassified), and 84.1% when using pTau217 (11.2% misclassified). Stricter thresholds (95%–95% and 97.5%–97.5%) further reduced misclassification rates but at the expense of fewer avoidable invasive procedures.

Conclusions

Plasma pTau217 (alone or combined with Aβ 42 ) shows high accuracy for detecting AD pathology and could serve as a scalable, noninvasive diagnostic tool. This approach may triage patients for confirmatory testing and substantially reduce the need for invasive CSF examination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-Peptidestau ProteinsPeptide FragmentsAlzheimer DiseaseCognitive DysfunctionHumansMaleFemaleRetrospective StudiesAgedMiddle AgedBiomarkersAged, 80 and overROC Curve

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerscerebrospinal fluidplasma

Substanzen

Amyloid beta-Peptidestau ProteinsPeptide FragmentsBiomarkersamyloid beta-protein (1-42)MAPT protein, human

Autor:innen und Institutionen

  • SC Neurologia, Ospedale Maria Vittoria, Torino, Italy.
  • Centro regionale Diagnosi Osservazione Malattie Prioniche - Laboratorio di Neurobiologia, Ospedale Maria Vittoria, Torino, Italy.
  • SCDU Malattie Infettive, Dipartimento di Scienze Mediche - Università di Torino, Ospedale Amedeo di Savoia, Torino, Italy.
  • SC Neurologia, A.O. S. Croce e Carle, Cuneo, Italy.
  • SC Neurologia, Nuovo Ospedale degli Infermi, Ponderano, Italy.
  • SC Neurologia, Ospedale San Giacomo, Novi Ligure, Italy.

ORCID-Profile: Daniele Imperiale, Mario Coletti Moja, Marco De Mattei

Zitieren

APA

Imperiale, D., Marcinnò, A., Atzori, C., Angeloro, D. P., Murgioni, A., Bagatin, A., Secci, V., Calcagno, A., Capobianco, M. A., Coletti Moja, M., Rota, E., Rosso, M., Bongioanni, M. R., Godi, L., Barra, M., De Mattei, M., Bonzanino, M., Ferrandi, D., Rainero, I., …, & Bozzali, M. (2025). Plasma pTau217/Aβ 42 and pTau217 outperform pTau181/Aβ 42 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251390897

Vancouver

Imperiale D, Marcinnò A, Atzori C, Angeloro DP, Murgioni A, Bagatin A, et al. Plasma pTau217/Aβ 42 and pTau217 outperform pTau181/Aβ 42 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251390897

BibTeX
@article{Imperiale2025,
  author = {Imperiale, Daniele and Marcinnò, Andrea and Atzori, Cristiana and Angeloro, Daniele Pio and Murgioni, Amelia and Bagatin, Alessia and Secci, Valentina and Calcagno, Andrea and Capobianco, Marco Alfonso and Coletti Moja, Mario and Rota, Eugenia and Rosso, Mara and Bongioanni, Maria Roberta and Godi, Laura and Barra, Massimo and De Mattei, Marco and Bonzanino, Massimo and Ferrandi, Delfina and Rainero, Innocenzo and Lopiano, Leonardo and Bozzali, Marco},
  title = {Plasma pTau217/Aβ 42 and pTau217 outperform pTau181/Aβ 42 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  doi = {10.1177/13872877251390897}
}
Kostenlos starten →